OCU400 Low Dose ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 90 | Retinitis pigmentosa | 1 |
90. Retinitis pigmentosa
Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05203939 (ClinicalTrials.gov) | January 24, 2022 | 16/11/2021 | The Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa | A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 (Nuclear Receptor Subfamily 2 Group E Member 3) and RHO (Rhodopsin) Mutations | Retinitis Pigmentosa | Drug: OCU400 Low Dose;Drug: OCU400 Mid Dose;Drug: OCU400 High Dose | Ocugen | NULL | Recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United States |